Trial Profile
A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750- 2000 mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2017
Price :
$35
*
At a glance
- Drugs Licarbazepine (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions
- Sponsors Novartis
- 01 Mar 2017 New trial record.